Welcome to the upgraded BRAC University Institutional Repository. We are currently organizing collections after a recent system upgrade. Homepage category counters may temporarily show lower numbers while syncing, but over 27,000 repository items remain safe and accessible. Please use the search bar to find theses, scholarly outputs, and institutional documents.

Regulating diabetes during COVID-19 – a review

bracu.degree.levelUndergraduate
bracu.type.groupStudent Works
datacite.rightsOpen Access
dc.contributor.advisorJamiruddin, Mohd. Raeed
dc.contributor.authorFarzana, Atika
dc.contributor.departmentSchool of Pharmacy
dc.date.accessioned2025-01-13T04:52:20Z
dc.date.available2025-01-13T04:52:20Z
dc.date.copyright©2023
dc.date.issued2023-06
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 22-33).
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.en_US
dc.description.abstractInspite of having no significant relationship with SARS CoV-2 infection, diabetes takes to disease severity which tends to mortality often. Patients having poor blood glucose management are susceptible to death more in COVID-19. The threshold of decreased death risk is between6 3.9 and 10.0 mmol/L. According to investigations, due to infections of COVID-19, diabetic patients had major problems and died. Diabetic patients have to experience significant COVID-19 problems including severe symptoms and consequences. So, scientists say that well-controlled diabetes can decrease getting ill from COVID-19. So, diabetic patients have to take foods, fruits and liquid, sweetened drink, honey in the time of increasing blood sugar and dropping blood sugar respectively. Anyway, for diabetic patients, insulin and metformin are commonly used to regulate blood glucose in COVID-19 individuals. Few applications of drugs are also used for diabetic patients which may affect the course of the COVID-19. GLP-1R agonists, SGLT2 inhibitors, DPP4 inhibitor and PPARs are included here. However, For the COVID-19 environment, diabetes treatment should be provided adequately.en_US
dc.description.degreeBachelor of Pharmacy
dc.description.statementofresponsibilityAtika Farzana
dc.format.extent43 pages
dc.identifier.otherID 18346056
dc.identifier.urihttp://hdl.handle.net/10361/25134
dc.language.isoenen_US
dc.publisherBRAC Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectDiabetes mellitusen_US
dc.subjectCOVID-19en_US
dc.subjectSARS COV-19en_US
dc.subjectSGLT2 inhibitorsen_US
dc.subjectGlucagon-like peptide-1en_US
dc.subjectSodium-glucose Cotransporter -2en_US
dc.subjectDPP4en_US
dc.subject.lcshCOVID-19 Pandemic, 2020---Influence--Health aspects.
dc.subject.lcshCOVID-19 Pandemic, 2020---Physiological aspects.
dc.subject.lcshDiabetes.
dc.titleRegulating diabetes during COVID-19 – a reviewen_US
dc.typeThesisen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
18346056_PHR.pdf
Size:
418.31 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: